-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $80

Benzinga·02/04/2026 14:27:12
Listen to the news
Barclays analyst Gena Wang maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $90 to $80.